Comparative efficacy and safety of bi-flanged metal stents versus lumen-apposing metal stents for endoscopic drainage of pancreatic fluid collections: a systematic review and meta-analysis.

Eur J Gastroenterol HepatolMar 27, 2026 (epub)
Clinical ResearchGastroenterology

Muhammad Shahzil, Muhammad Hashim Faisal, Muhammad Hammad Khan et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared bi-flanged metal stents (BFMS) with lumen-apposing metal stents (LAMS) for endoscopic ultrasound-guided drainage of pancreatic fluid collections. Three comparative studies included 627 patients (329 treated with BFMS and 298 with LAMS). The pooled analysis found no significant differences in technical success (OR 1.16; 95% CI 0.55-2.43) or clinical success (OR 0.97; 95% CI 0.51-1.87). Recurrence, procedural burden and reported adverse events were also comparable, supporting the authors’ conclusion that either stent is a viable option.

Key findings

  • Technical success did not differ significantly between BFMS and LAMS (OR 1.16; 95% CI 0.55-2.43).
  • Clinical success was similar with BFMS and LAMS (OR 0.97; 95% CI 0.51-1.87).
  • No differences were observed in walled-off necrosis recurrence, necrosectomy sessions or mean number of endoscopic procedures.
  • Bleeding, infection, stent migration and stent occlusion or dysfunction were comparable between groups.

Why it matters

Both stent types are used to drain pancreatic fluid collections, but comparative evidence has been limited. This pooled analysis suggests that neither device showed a clear advantage in efficacy, procedural burden or safety across the included studies. The findings can inform consideration of stent options while highlighting that the available comparative evidence remains limited.

What to keep in mind

Only three comparative studies were included. The authors call for larger prospective studies to refine stent selection.

Source

Published in Eur J Gastroenterol Hepatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.